1Fukuhara A, Matsuda M, Nishizawa M,et al. Visfatin : a protein secreted by visceral fat that mimics the effects of insulin [J]. Science,2005,307 ( 5708 ) : 426-430.
2Samal B, Sun Y, Stearns G,et al. Cloning and characterization of the cD- NA encoding a novel human pre-B-cell colony-enhancing factor [J]. Mol Cell Biol, 1994,14(2) : 1431-1437.
3Kitani T,Okuno S,Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-eell colony-enhancing factor [J]. FEBS Lett, 2003,544 ( 1-3 ) : 74-78.
4Rongvaux A,Shea R J, Mulks MH, et al. Pre-B-ce11 colony-enhancing factor, whose expression is up-regulated in activated lymphocytes,is a nicotina- mide phosphoribosyltransferase,a cytosolic enzyme involved in NAD+ biosynthesis[J]. Eur J Immunol, 2002,32 ( 11 ) : 3225-3234.
5Vander Veer E, Nong Z, O' Nell C, et al. Pre-B-cell colony-enhancing factor regulates NAD +-dependent protein deacetylase activity and pro- motes vascular smooth muscle cell maturation[J]. Circ Res, 2005,97 ( 1 ) : 25-34.
6Sethi JK, Vidal-Puig A. Visfatin:the missing link between intra-abdomi- nal obesity and diabetes[J]. Trends Mol Med, 2005,11 (8) .. 344-347.
7Haider DG, Schindler K, Schaller G,et al. Increased plasma visfatin con- centrations in morbidly obese subjects are reduced after gastric banding [J]. J Clin Endocfinol Metab, 2006,91 (4) : 1578-1581.
8Mu J ,Feng B,Ye Z,et al. Visfatin is related to lipid dysregulation,en- dothelial dysfunction and atherosclerosis in patients with chronic kidney disease [J]. J Nephrol, 2011,24 (2) : 177-184.
9Chang YC, Chang TJ, Lee WJ ,et al. The relationship of Visfatin/pre-B- cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation,insulin resistance, and plasma lipids [J]. Metabolism, 2010,59 ( 1 ) : 93-99.
10Kadoglou NP, Gkontopoulos A, Kapelouzou A, et al. Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study [Jl.Clin Chim Aeta,2011,412(1-2) :48-52.
二级参考文献19
1Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 2005 , 307(5708) : 426-430.
2Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol, 2007 , 178 (3): 1748-1758.
3Dahl TB, Yndestad A, Skjelland M, etal. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation,2007,115(8) :972-980.
4Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol., 1983;51 (3) :606.
5Adya R, Tan BK, Chen J, et al. Nuclear faetor-kappaB induetion by visfatin in human vaseular endothelial cells: its role in MMP-2/9 production and activation. Diabetes Care,2008,31 (4):758-760.
6Haider DG, Holzer G, Sehaller G, et al. The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr,2006;43(4) :548-549.
7Tilg H, Mosehen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) ,2008, 114(4) :275-288.
8Adya R, Tan BK, Punn A, et al. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatininduced angiogenesis. Cardiovasc Res, 2008 , 78 (2) : 356-365.
9Kim SR, Bae YH, IMe SK, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta,2008;1783 (5) :886-895.
10BULCAO C, FERREIRA S R, GIUFFRIDA F M, et al. The new adipose tissue and adipocytokines[J]. Curr Diabetes Rev, 2006,2 : 19-28.
1Sbrana F,Cocci F,Papa A,et al.Routine laboratory tests to risk-stratify patients with chronic coronary artery disease[J].J Cardiol,2013,61(2):132-137.
2Hu W,Liu CW,Su J,et al.Elevated plasma visfatin concentrations in patients with community-acquired pneumonia[J].Peptides,2013,43:8-12.
3S.Mohammadi,M.Javad,Hosseinzadeh-Attar,et al.Compare the effects of different visfatin concentration on cardiovascular risk factors,adiponectin and insulin resistance in patients with T2DM[J].Diabetes Meatab Syndr,2011,5(2):71-75.
